Press Releases

• Oct 13, 2021 Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering
• Oct 12, 2021 Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering
• Sep 22, 2021 Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021
• Sep 15, 2021 Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress
• Sep 9, 2021 Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism
• Sep 7, 2021 Rezolute to Participate in Upcoming Virtual Healthcare Conferences
• Aug 10, 2021 Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME
• Aug 3, 2021 Rezolute to Participate in Upcoming Virtual Healthcare Conferences
• Jun 28, 2021 Rezolute Added to Russell Microcap® Index
• May 27, 2021 Rezolute to Participate in Upcoming Virtual Healthcare Conferences
• May 20, 2021 Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs
• May 18, 2021 Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board
• May 17, 2021 Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress
• May 17, 2021 Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit
• May 4, 2021 Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema
• Apr 19, 2021 Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners
• Mar 22, 2021 Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021
• Mar 8, 2021 Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts
• Mar 2, 2021 Rezolute to Participate in Upcoming Investor Conferences in March
• Feb 10, 2021 Rezolute Reports Second Quarter Fiscal 2021 Financial Results
• Jan 12, 2021 Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
• Dec 28, 2020 Rezolute Announces Change of Transfer Agent
• Dec 3, 2020 FDA Clears Rezolute’s IND Application for RZ402
• Nov 19, 2020 Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
• Nov 5, 2020 Rezolute Announces Uplisting to the Nasdaq Capital Market
• Oct 9, 2020 Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq
• Sep 10, 2020 Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors
• Jul 27, 2020 Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism
• Jun 15, 2020 Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science
• Jun 10, 2020 Rezolute Receives Rare Pediatric Disease Designation for RZ358, Phase 2b Candidate for the Treatment of Congenital Hyperinsulinism, Enabling Eligibility for Priority Review Voucher
• Jun 1, 2020 Rezolute Presents RZ358 Clinical Data-Validated Model of the Pharmacokinetics and Glycemic Response in Congenital Hyperinsulinism at Pediatric Endocrine Society 2020 Annual Meeting
• May 28, 2020 Rezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting
• May 14, 2020 Rezolute, Inc. Announces Updates to Clinical and Business Operations in Response to COVID-19 Pandemic
• Feb 10, 2020 Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism
• Jan 27, 2020 Rezolute to Present at BIO CEO & Investor Conference 2020
• Dec 18, 2019 Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes
• Dec 2, 2019 Rezolute Management to Present at 2020 Biotech Showcase Conference
• Nov 25, 2019 Rezolute Appoints Nektar Therapeutics COO & CFO to Its Board of Directors
• Oct 11, 2019 Rezolute Management to Present at 2019 BIO Investor Forum Conference
• Aug 5, 2019 Rezolute Management to Present at 2019 Canaccord Genuity Growth Conference
• Jul 24, 2019 Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option
• Jan 7, 2019 Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million
• May 16, 2018 Rezolute Announces Appointment of Keith Vendola as Chief Financial Officer
• Apr 9, 2018 Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development
• Apr 4, 2018 Rezolute Announces Appointment of Hoyoung Huh, M.D., Ph.D. as Vice Chairman of its Board of Directors
• Apr 3, 2018 Rezolute, Inc. Announces Close of Convertible Note Financing
• Dec 26, 2017 UPDATE - Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC
• Dec 7, 2017 AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.
• Oct 17, 2017 AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema
• Oct 9, 2017 AntriaBio Appoints Nektar Therapeutics CFO to its Board of Directors
• Oct 4, 2017 AntriaBio Appoints Dr. Robert Bhisitkul to its Scientific Advisory Board
• Aug 7, 2017 AntriaBio and ActiveSite Pharmaceuticals Announce License and Development Agreement for Plasma Kallikrein Inhibitors
• Jul 25, 2017 AntriaBio Announces First Patient Dosed in Phase 1 Clinical Study of AB101
• Jul 17, 2017 AntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This Month
• Jun 5, 2017 AntriaBio Files Investigational New Drug Application for Once-Weekly Basal Insulin AB101
• May 1, 2017 AntriaBio Formally Engages CRO for the Conduct of its Phase I First-in-Human Clinical Trial of AB101
• Mar 22, 2017 AntriaBio Appoints Two Pharmaceutical Executives to its Board of Directors
• Dec 15, 2016 AntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common Stock
• Sep 22, 2016 AntriaBio Announces Formation of Subsidiary and Plan to Raise Capital in South Korea
• Jun 29, 2016 AntriaBio Announces $12 Million Private Placement
• Jun 22, 2016 AntriaBio Announces Preclinical Proof of Concept for Once-Weekly Basal Insulin AB101 in Diabetic Miniature Swine
• Jan 6, 2016 AntriaBio Announces Appointment of Michael Deperro as Vice President of Operations
• Dec 10, 2015 AntriaBio Announces First Close of Private Placement Transaction
• Nov 17, 2015 AntriaBio Receives Notice of Allowance on Patent Covering Microsphere Drug Delivery Platform
• Sep 16, 2015 AntriaBio Announces New Product Candidate, AB301, a Weekly GLP-1 Agonist and Basal Insulin Combination, for Type 2 Diabetes
• Jun 29, 2015 AntriaBio Appoints David F. Welch, Ph.D. to Its Board of Directors
• Jun 8, 2015 AntriaBio Announces Promising Preclinical Results for Once-Weekly Basal Insulin AB101
• May 11, 2015 AntriaBio to Present New Preclinical Data at the American Diabetes Association 75th Scientific Sessions
• Jan 8, 2015 AntriaBio Announces Appointment of Dr. Hoyoung Huh as Chairman of Scientific Advisory Board and Business Development
• Jan 7, 2015 AntriaBio Announces Completion of PK/PD Studies of AB101 in Two Species
• Jan 5, 2015 AntriaBio Announces $7 Million Private Placement
• Nov 10, 2014 AntriaBio Extinguishes $44 Million Contingent Liability
• Jul 23, 2014 AntriaBio Appoints Barry Sherman, M.D. to Its Board of Directors
• Jun 23, 2014 AntriaBio Appoints C. Ronald Kahn, M.D. to Its Scientific Advisory Board
• May 22, 2014 AntriaBio, Inc. to Present at the Third Annual Marcum MicroCap Conference on Thursday, May 29, 2014
• May 12, 2014 AntriaBio, Inc. Establishes Manufacturing and Laboratory Facility in Colorado
• May 1, 2014 AntriaBio, Inc. Announces 1-for-6 Reverse Stock Split
• Apr 30, 2014 AntriaBio, Inc. Launches Digital Corporate Communication Channels
• Apr 23, 2014 AntriaBio Announces Formation of Scientific Advisory Board
• Apr 2, 2014 AntriaBio, Inc. Announces $10 Million Private Placement
• Mar 6, 2014 AntriaBio, Inc. to Present at 26th Annual ROTH Conference
• Feb 5, 2014 AntriaBio to Present at 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014
• Jan 16, 2014 AntriaBio Announces Closing of Bridge Financing
• Jul 24, 2013 AntriaBio Granted European Patent Allowance for Method of Preparing Site-Specific Protein Conjugates
• Jul 1, 2013 AntriaBio Initiates Effort to Raise up to $12 Million in a Private Placement
• Feb 19, 2013 AntriaBio Appoints Two Industry Leaders to Its Management Team
• Feb 8, 2013 AntriaBio Announces Stock Ticker Symbol Change to ANTB
• Feb 6, 2013 UPDATE: AntriaBio Completes Merger and Elects Board of Directors
• Jan 7, 2013 AntriaBio Acquires Assets of PR Pharmaceuticals and Announces Intent to Merge With a Public Company